![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 14, 2019 12:10:35 PM
I only managed to ask 2 questions right at the end cause had trouble un-muting the phone.
Faz started the call by giving a quick overview of SugarBeat, benefits, marketing and plans for Europe.
Key Points
Transmitter - Will last for 3 years
Daily Disposable - Same manufacturing process as other daily disposables
So the parts are minimal cost
Marketing - 2 Prong Approach
They are speaking with several companies regarding collaboration with SugarBeat. These companies have significant access to a captive audience. Faz said they are in discussion with several such partners.
Also, the NHS is actively funding. They are interested in anything to do with diabetes prevention and reversal. SugarBeat is ideally positioned.
So they are in discussion with number of parties in UK who have substantial presence in Diabetes market.
DallasBurston - Will offer various subscription based models on their website which will be ready for next quarter. This is for consumers to access directly and self fund.
Faz described Dallas as having an impeccable record of bringing products to enormous success.
Next month they will be presenting in front of several thousand experts in diabetes.
So NMRD want to establish and build a robust presence in the UK. They will then push into Germany, France, Italy, Spain... then Mid East...
Apparently they have only received the branding/literature. Alot of the electronic parts are on a 30/40week lead time and this is one of reasons why they placed the initial order last year.
FDA. They expect to have communciation back in 3months time from submission. We are in week 5 already.
The transmitter is single (bluetooth) communication but can be used on multiple apps.
Someone brought up about how much NHS pays per month? Finger Prick Testing is £40/45 and is funder, Abbott is Double this..
If think of anything else will let you know.
Recent NMRD News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 04/19/2024 08:05:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2024 08:16:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:05:11 PM
- Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET • GlobeNewswire Inc. • 01/22/2024 09:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/17/2024 10:17:04 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/17/2024 10:15:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 10:30:57 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 10:29:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 12:00:07 PM
- Important Update on Listing Status and Strategic Direction • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 01:00:08 PM
- Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision • GlobeNewswire Inc. • 12/13/2023 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/07/2023 03:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2023 01:38:51 PM
- Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth • GlobeNewswire Inc. • 11/21/2023 01:30:00 PM
- Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs • GlobeNewswire Inc. • 11/14/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:15:26 PM
- Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 09:14:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 08:05:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:10:28 PM
- Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs. • GlobeNewswire Inc. • 09/26/2023 01:50:00 PM
- Maxim Group LLC to Host the Virtual Tech Conference Series: Emerging Growth in A.I., on Tuesday, September 26th & Wednesday, September 27th at 8:00 A.M. ET. • GlobeNewswire Inc. • 09/22/2023 07:05:36 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM